Abstract This review evaluates the serotype epidemiology of complicated pneumococcal pneumonia (CPP) during the period 1990-2012. PubMed and EMBASE were searched using the terms "empyema", "complicated pneumonia", "pleural infection", "necrotizing pneumonia", "pleural effusion", "parapneumonic effusion", "pneumatocele", or "lung abscess"; "pneumococcal" or "Streptococcus pneumoniae"; and "serotype" for studies on the epidemiology of complicated pneumonias published from
Introduction
Streptococcus pneumoniae is the most common cause of pneumonia in children and a major cause of pneumonia in adults worldwide [1, 2] . Among patients with pneumonia, as many as half may develop pleural effusions (i.e., fluid in the pleural space); of these, 5-10 % may progress to empyema [3] . In general, "complicated pneumonia" refers to pneumonia accompanied by pleural effusion. Empyema is a serious complication characterized by pus and bacteria in the pleural space [3, 4] , which may progress to necrosis, cavitation, or fistulas in the thoracic cavity. S. pneumoniae is the most common cause of complicated pneumonia in children and a common cause in adults [5, 6] . Other bacteria associated with acute complicated pneumonias include S. pyogenes, S. milleri, Staphylococcus aureus, Haemophilus influenzae, Mycoplasma pneumoniae, Pseudomonas aeruginosa, other Streptococcus species, and, less commonly, Klebsiella, Enterobacter, Proteus, Salmonella, and Yersinia species [5] .
The reported incidence and proportion of cases of complicated pneumococcal pneumonia (CPP) in children and adults have increased in recent decades [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . This trend has been described both before and after the introduction in 2000 of the 7-valent pneumococcal conjugate vaccine (PCV7; serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F conjugated to CRM 197 ) for pediatric vaccination. A 23-valent pneumococcal polysaccharide vaccine (PPV23) containing pneumococcal capsular polysaccharides (serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F) was introduced in 1983 for the vaccination of children and adolescents at high risk of pneumococcal disease, but primarily older adults. Unlike the pneumococcal conjugate vaccines, PPV23 is not approved for children aged <2 years. PPV23 in adults has been shown to have an impact on bacteremic pneumococcal pneumonia, but not all-cause pneumonia [20, 21] . More recently, the 10-valent pneumococcal conjugate vaccine (PCV10; serotypes 1, 4, 5, 6B, 7F, 9V, 14, and 23F conjugated to non-typeable H. influenza protein D, serotype 18C conjugated to tetanus toxoid, and serotype 19F conjugated to diphtheria toxoid) and the 13-valent pneumococcal conjugate vaccine (PCV13; serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F conjugated to CRM 197 ) were introduced beginning in 2009 (Table 1) .
A limited number of pneumococcal serotypes have been associated with CPP and pneumococcal empyema (PnEmp). Changes in the serotype epidemiology of invasive pneumococcal disease (IPD) and pneumococcal pneumonia have been reported in recent years, with significant declines in incidence and in the proportion of disease caused by PCV7 serotypes and increases in the proportion of non-PCV7 serotype disease [22] [23] [24] [25] [26] [27] . Although these changes are suggestive of serotype replacement, similar trends have also been reported in some countries prior to the introduction of PCV7 [28, 29, 68] .
The purpose of this review is to evaluate the serotype epidemiology of CPP during the period 1990-2012.
Methods
PubMed and EMBASE were searched for studies on the epidemiology and incidence of CPP published from January 1, 1990 through October 1, 2013 using the terms: "empyema", "complicated pneumonia", "pleural infection", "necrotizing pneumonia", "pleural effusion", "parapneumonic effusion", "pneumatocele", or "lung abscess"; "pneumococcal" or "Streptococcus pneumoniae"; and "serotype". Studies with data on incidence, prevalence (i.e., proportion of cases), or serotypes were included; reviews, case reports, and conference abstracts were excluded. In addition, the references sections of relevant review articles were checked for studies not identified during the online search.
The base population used for analyses varied by study. For example, among studies of incidence or proportion of complicated pneumonias or empyema, the base populations included: hospitalized patients [13] or hospitalized patients with community-acquired pneumonia (CAP) [19, [30] [31] [32] ; pneumococcal pneumonia [9, 16, [32] [33] [34] [35] [36] [37] [38] [39] [40] ; IPD [10, 12, 17, 18, [41] [42] [43] [44] [45] [46] [47] [48] [49] ; complicated pneumonia [7, 13, [50] [51] [52] [53] [54] ; complicated pneumonia with positive cultures [14] ; CPP [55] ; empyema [56] [57] [58] [59] [60] [61] ; or empyema with fistula [62] . Some studies described the clinical methodologies used to identify pleural effusion or empyema prior to microbiological identification. Retrospective studies used: diagnostic coding [16, 19, 30, 31, 35, 52, 61] ; records of chest radiographs [9, 33, 48, 50] ; computed tomography (CT) [7, 9, 34, 50] ; ultrasound [7, 34, 50, 56] ; microbiologic culture records [13] ; or results at surgery [56] . One study reviewed "pleural effusion data", although no other details were specified [48] . Prospective studies used: thoracocentesis [39, 51, 53, 54] ; CT, ultrasound, or chest radiograph plus clinical signs [58] ; CT, ultrasound, or chest radiograph [32] ; or physical examination and chest radiograph [37, 60, 63] . One study did not specify the diagnostic methodology [49] .
Studies varied in the methodologies used to isolate S. pneumoniae, including: culture of samples from the pleural cavity [7, 13, 49-51, 54, 58, 62, 64-66] , blood [32, [68] [69] [70] [71] , blood and pleural cavity [9, 10, 14, 15, 17, 18, 30, 31, 34-36, 38, 41-48, 52, 53, 56, 57, 63, 72-90] , or unspecified sites [33, 40, 91] ; and, more recently, investigators used polymerase chain reaction (PCR) or real-time PCR to identify pneumococcal-specific genes (e.g., ply, LytA, rpoB, or wzg [cpsA]) in samples from the pleural cavity [43, 46, 49, 51, 53-55, 58, 60, 64, 67, 87, 88, 90, 92-94] , blood [15, 32, 37, 75, 95] , blood and pleural cavity [88] , or nasopharyngeal aspirate [96] . A few studies applied immunochromatographic pneumococcal antigen detection (Binax NOW®) from blood or urine [15, 38, 51, 74, 77, 84] .
Pneumococcal serotypes in blood or pleural fluid were identified with the Quellung reaction (also referred to as capsular swelling) [7, 12, 14, 15, 17, 18, 30, 31, 34-38, 40, 42-49, 56, 68, 69, 71, 73, 77, 82, 85-88, 90-93] , dot blot [47, 71, 93] , slide or latex agglutination [8-10, 40, 63, 65, 70, 72, 77, 80, 81, 83, 84, 97, 98] , enzyme-linked immunoassays [55, 99] , real-time PCR [32, 37, 43, 44, 46, 49, 51, 64, 65, 87, 88, 90, 93, 95] , or multiplex PCR [54, 58, 60, 67, 74, 84, 92, 94, 97] . The Quellung reaction may include up to all the known serotypes, whereas PCR is typically more limited in the serotypes that can be identified. Some studies used more than one methodology (e.g., initial serotyping of cultured isolates, followed by PCR in culture-negative samples) [37, 65, 87, 88, 93, 94] .
Definitions of penicillin susceptibility varied; some studies used breakpoints established by the Clinical and Laboratory Standards Institute (CLSI) in 2009 [53, 74, 83, 88, 90, 100] , whereas others used pre-2009 breakpoints [7, 9, 15, 17, 30, 34, 63, 73] .
Results
A total of 152 papers were initially identified; 68 were excluded because there were no data on incidence or serotypes, or they were case reports; consequently, 84 were included in this analysis. Table 2 presents data on the incidence and proportion of CPP [7, 9, 10, 12-14, 16-19, 30-47, 49-62] . Trends and agerelated differences in the studies are discussed below.
Incidence
The incidence of any-cause empyema among children aged <19 years in Utah (USA) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) [30, 31] and Australia (1998-2010) [19] ranged from 0.9 to 12.5 per 100,000 population, and tended to increase over time; the incidence was highest in children aged 0-4 years ( Table 2 ) [19] . Likewise, in Spain from 1997-2001 to 2002-2006, the PnEmp incidence was lower in children aged 5-17 years (0.5-1.3 per 100,000 population) as compared to younger children [12] . In 1996-2001 and 2006-2009, the adult PnEmp incidence was higher in those aged >65 years (3.5-4.8 per 100,000) than other adult age groups (0.5-1.8 per 100,000) ( Table 2 ) [17] .
The incidence for PnEmp tended to increase from the late 1990s to the mid-2000s in children in the USA [10, 16] and Spain [12] , but remained lower in children aged 5-17 years compared with younger children (Table 2 ) [12] . For example, the PnEmp incidence among children aged <18 years in Utah (USA) increased from 10.3 per 100,000 population in 1996-2000 to 14.3 per 100,000 population in 2001-2003 [10] , and increased in children aged 2-4 years in the USA from 1.1 to 2.5 per 100,000 population from 1996-1998 to 2005-2007, respectively [16] . In Spain from 1997-2001 to 2002-2006, the PnEmp incidence increased from 2.2 to 9.2 per 100,000 population in children aged <2 years and from 1.5 to 9.2 per 100,000 population in children aged 2-4 years [12] . Of note, two studies from Spain showed significant declines in the PnEmp incidence following the introduction of PCV13 into the pediatric immunization program: in one, from 6.73 to 4.14 Proportion of cases with CPP Outcomes used as numerators for proportions of cases with CPP ranged from more general (e.g., pulmonary complications, complicated pneumonia) to more specific (e.g., empyema, cavitatory disease). Denominators varied, including hospitalized patients, hospitalized patients with CAP, hospitalized patients with pneumococcal CAP, or children with parapneumonic PnEmp. In addition, the assessment methods varied in sensitivity, which may have affected the reported proportions. For example, in hospitalized children with empyema in Australia, only 7.5 % of pleural fluid cultures, but 51.0 % of pleural fluid PCRs, were pneumococcal-positive [58] .
The proportion of cases of CPP or PnEmp among hospitalized children with pneumococcal pneumonia or IPD ranged from 7.9 to 71.4 % ( Table 2 ) and tended to increase over time [9, 10, 12, 16, 18, 32-37, 41, 44-46, 49] . [10, 18, 41, [44] [45] [46] 49] . Among hospitalized children with CAP in Utah (USA), the proportion of cases of complicated pneumonia and empyema increased from 13 % in 1994 to 41 % in 1997 [30] . Among children with complicated pneumonia or empyema, the proportion of cases of PnEmp as reported in several countries ranged from 0 to 54.4 %, although the sample sizes were often small [7, 13, 14, 49, 50, [52] [53] [54] [55] [56] [57] [58] [59] [60] 62] .
Among hospitalized adults with pneumococcal CAP, the proportions of cases with pleural effusion (PE) (15.2-19.5 %, Spain) [38, 39] were higher than those for PnEmp (6.4 %, Spain) [38] or necrotizing pneumonia (6.5-6.6 %, USA) [40] . Among hospitalized adults with IPD in Spain, 6.9-15.0 % were diagnosed with PnEmp (Table 2) [17, 47] . Effect of age on the incidence and proportion of cases of CPP The effect of age on CPP was not consistent across studies, and age effects for incidence differed as compared to proportion. In most studies, older children comprised a larger proportion of those with CPP or PnEmp relative to other pneumococcal diseases. In Utah (USA) (1997-2010), children with CPP were significantly older than those with other forms of IPD (37 months vs. 25 months; p<0.001) [18] . Among children with pneumococcal pneumonia in the USA (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) , the proportion of cases with CPP increased with age from 26.4 % (ages 0-12 months) to 53.0 % (ages >61 months) [34] . In contrast, in a study of children from four Asian countries (Vietnam, China, Korea, and Taiwan), empyema and PE were most common in the younger age groups, particularly those ≤4 years of age [13] .
The pattern of age-specific incidence may differ from that of the proportion of cases. For example, among hospitalized children with IPD in Spain (1997 Spain ( -2006 , the proportion of cases with PnEmp increased with age from 6.9-17.9 % (ages <2 years) to 21.4-33.3 % (ages 5-17 years), whereas the PnEmp incidence declined with age from 2.2-9.2 per 100,000 population (ages <2 years) to 0.5-1.3 per 100,000 population (ages 5-17 years), which seems to parallel the pattern of IPD incidence among children [12] . In particular, in another study in Spain (2007 Spain ( -2012 , the PnEmp incidence was greater among children aged ≥24 to <60 months (8.55-13.81 per 100,000 population) than among younger (<12 months: 1.78-1.36 per 100,000 population) or older (5-15 years: 1.53-2.36 per 100,000 population) children [49] .
In Spain (1996 Spain ( -2009 , although adults aged 50-65 years had a higher proportion of cases of PnEmp (17.3 %) than adults aged >65 years (12.7 %), the PnEmp incidence was lower among adults aged 50-65 years than those aged >65 years (1.4 vs. 4.8 per 100,000 population, respectively) [17] , which is consistent with the trend of age-specific incidence of IPD with aging. [54] , and 36.4 % of PnEmp cases in children in Australia [58] .
Serotype epidemiology
Serotypes varied in their prevalence as complicated versus uncomplicated pneumonia. In children in Utah (USA) (1997- PnEmp in Spain (2003 Spain ( -2006 identified the same three serotype 1 clones in pleural fluid [87] . MLST types associated with the increased incidence of pediatric PnEmp had been present previously in Spain and elsewhere in Europe, and, therefore, the increase in proportions of PnEmp (predominantly serotype 1) was probably not associated with the emergence of new clones or of capsular switching [87, 101] . For adults in Spain (1996 Spain ( -2010 , an increase in PnEmp incidence in otherwise healthy adults with pneumonia was associated predominantly with serotype 1, in particular, ST306 [47] .
Antibiotic resistance
Antibiotic sensitivity data are available from CPP isolates, which are predominately the serotypes 14, 1, and 19A; among these three predominant PCV13 serotypes, only 19A tends to be associated with antibiotic resistance (probably due to its relationship with nasopharyngeal carriage). Among children in Utah (USA) (1993-1999), PnEmp was less likely than uncomplicated pneumococcal pneumonia to be caused by penicillin-resistant pneumococci (16 % vs. 48 %; p=0.0021); all serotype 1 isolates were penicillin-susceptible [30] . For pediatric CPP in Tennessee (USA) (1996-2001), all serotype 1 isolates (n=5) were susceptible to penicillin, whereas 5 of 7 serotype 14 isolates (the most frequently identified isolate in this sample) were penicillin-resistant [7] . (By contrast, in eight children's hospitals in the USA (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) , the antibiotic resistance rates were similar among isolates from CPP and uncomplicated pneumococcal pneumonias [34] .) Serotype 19A is associated with reduced sensitivity to antibiotics [15, 53, 83, 90] . In Spain, 11 % of cases of pediatric PnEmp were caused by serotype 19A; all three culturepositive serotype 19A isolates were non-susceptible to cefotaxime, and two were also non-susceptible to parenteral penicillin [90] . Other serotypes isolated in this study (1, 5, and 7F) were susceptible to parenteral beta-lactams and showed low rates of resistance to oral penicillin and erythromycin. In another Spanish study (2003) (2004) (2005) (2006) [53] .
Several studies evaluated the association of pneumococcal conjugate vaccine introduction with antibiotic resistance among pneumococcal serotypes associated with CPP or PnEmp. In Israel (1990 Israel ( -2002 , no penicillin-resistant pneumococci were 1,000,000 children from 2006-2007 to 2010-2011 (incidence rate ratio, 4.17; 95 % CI, 1.53-14.2) [94] .
Although in some studies the emergence of serotypes 1, 19A, 3, and 14 in CPP and PnEmp has corresponded to the years following the introduction of PCV7 [17, 18, 31, 35, 50, 52, 86] , a few studies demonstrated that their increasing role in CPP and PnEmp began prior to the introduction of PCV7 [28, 29, 68] . For example, in a study of IPD in Spain (1989 Spain ( -2008 , the proportion of cases of IPD caused by serotype 1 was increasing prior to the introduction of PCV7, and this trend continued after the introduction of PCV7 (2 %, 8.6 %, 14.9 %, and 23.8 % of cases in 1989-1993, 1994-1998, 1993-2003, and 2004-2008 , respectively [p<0.001]) [68] . This suggests that emergence involves more than simply serotype replacement following PCV7 introduction; characteristics particular to certain serotypes, such as differences in antibiotic sensitivity or their propensity to cause pleural infection, may be responsible for these increases. In addition, several studies established a relationship between the proportion of CPP and age that contrasts with the age-specific incidence of IPD [32, 40, 44, 49, 87, 90, 97] , which may suggest an interaction between the propensity of given serotypes to infect and the age-dependent susceptibility of patients to infection by these same serotypes.
Recent data suggest that PCV13 may impact on pediatric PnEmp caused by serotypes associated with CPP, such as 1 and 19A. In Spain, where PCV13 was introduced in 2010, the incidence of pediatric PnEmp caused by serotypes targeted by PCV13 declined significantly from 2009-2010 to 2010-2011 (5.52 vs. 3.55 per 100,000 population; p=0.049), mainly due to reductions in serotypes 1 (2.81 vs. 2.07 per 100,000 population) and 19A (1.51 vs. 0.69 per 100,000 population) [46] . More recently, in children aged <15 years in Spain, the PnEmp incidence declined significantly (p=0.0019) from 5.72 to. [49] .
Although this review has recapitulated the basic epidemiology of CPP (including PnEmp) over the past several decades, the increased use of more specific diagnostic imaging (e.g., CT and ultrasound) in recent years may affect the reported rate of PE and empyema because of the more accurate identification. Improved diagnostic methodologies, clinical (ultrasound or CT vs. physical examination or chest X-ray) and microbiological (e.g., PCR vs. culture), as well as increased awareness of and vigilance for PE and empyema may have resulted in an apparent increase in the proportion of CPP over the time period included in this analysis, which, given the limitations of the retrospective nature of this analysis, may be a confounding factor in the determination of any true increase in the proportion of CPP.
This review is also limited by the fact that many of the studies used culture to identify pathogens. Culture may be less than ideally sensitive to the presence of specific pathogens because of factors such as prior antibiotic use or other difficulties in culturing pathogens. In recent years, PCR has been applied to identify the pneumococci causing CPP and to identify serotypes in culture-negative specimens [32, 59, 64, 84, 87, 93] . As antibiotic treatment may reduce the likelihood of detecting bacteria via culture, PCR is useful in detecting pneumococci in culture-negative samples from patients previously treated with antibiotics. For example, in a Spanish study of culture-negative pleural fluid specimens from children with empyema, PCR typing identified eight different serotypes (i.e., serotypes 1, 3, 5, 7F/7A, 8, 14, 19A, and 19F/B/C) in 52 of 67 culture-negative pleural fluid samples from children with PnEmp, with a sensitivity of 96.0 % and a specificity of 98.6 % [93] . Spanish pediatric empyema patients with S. pneumoniae culture-negative/PCR-positive samples were found to be significantly more likely to have received antibiotics than those with culture-positive samples (92 % vs. 53 %, respectively; p<0.0001) [87] . Rapid pneumococcal antigen detection by means of immunochromatography has also been used to detect pneumococci in isolates from patients with empyema [51] . In hospitalized children with parapneumonic effusion, conventional microbiologic culture of pleural fluid samples detected pneumococci in 15 of 55 isolates, real-time PCR detected pneumococci in 13 of 16 culture-negative isolates (81.2 %), and immunochromatographic testing detected pneumococci in 24 of 27 culture-negative isolates (88.9 %) [51] . Such molecular methods may complete the information available on changes in the IPD and CPP serotype epidemiology over time.
Finally, most of the studies reviewed here used retrospective database analyses to identify cases of CPP and PnEmp. The specificity of information in these databases could vary, as cases may have been missed due to misclassification. In recent years, increased awareness of CPP and PnEmp has led to prospective surveillance studies, which may enhance disease identification. In addition, studies used different breakpoints to determine penicillin sensitivity, making it difficult to compare antibiotic resistance results.
In conclusion, the reported proportion of cases of CPP and PnEmp due to non-PCV7 serotypes has increased over the past several decades in countries that introduced PCV7 into the pediatric immunization program. Whether this increase reflects the advent and wider use of more specific diagnostic methods and increased awareness due to research initiatives, or if it, indeed, represents a true increase in disease incidence, is unclear. Several factors may account for these greater proportions, including enhanced disease detection due to a higher index of suspicion and more sophisticated diagnostic assays, as well as the prevalence of certain non-PCV7 serotypes that are capable of invading the pleural space.
It is established that reductions in the proportion of PCV7 serotype CPP have been observed in countries using PCV7.
Most serotypes associated with CPP and PnEmp-particularly serotypes 1, 19A, 3, and 7F-are targeted by PCV13, which was registered for pediatric vaccination from 2009 and for adult vaccination from 2011. Early reports suggest declines in the incidence and proportion of cases of vaccine serotype CPP post-PCV7 introduction, and then further with PCV13, although studies are ongoing.
